A Win-Win Multiple Sclerosis Deal? – Biogen Idec Inc. (BIIB), Elan Corporation, plc (ELN)

Biogen Idec Inc. (NASDAQ:BIIB) is buying the full rights to multiple sclerosis drug Tysabri from Elan Corporation, plc (ADR) (NYSE:ELN) for $3.25 billion. Investors are cheering Biogen and booing Elan based on the changes in their valuations today.

Seems about right to me.

Gaining full rights to the drug is a great move for Biogen. In addition to the upfront payment, Biogen owes a royalty of 12% for the first year, 18% on the first $2 billion in sales in subsequent years, and 25% on sales above $2 billion. But even with those payments, Biogen expects the deal to add $0.20 to $0.30 per share to the bottom line this year.

Biogen Idec Inc (NASDAQ:BIIB)More importantly, having full control over the sales and marketing of the drug should help Biogen’s overall business plan. The company also sells the multiple sclerosis drug Avonex and should have an oral drug for the condition — BG-12, to be sold under the brand name Tecfidera — approved by the Food and Drug Administration shortly.

The ability to coordinate promotion of the three drugs should minimize the cannibalization of sales, except when it makes sense for the company, and maximize the fight with Novartis AG (ADR) (NYSE:NVS)‘ Gilenya and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)s‘ Copaxone, its major competition in the oral and injected space respectively. Both Novartis and Teva should be very worried about how much stronger this deal has made Biogen.

The deal also gives Biogen full control over its own destiny. The biotech put itself up for sale in 2007, but couldn’t find a buyer, likely because a change in control gave Elan the ability to buy the rights to Tysabri away from a potential suitor. With that part of the partnership abolished, Biogen is more attractive as a takeout target.

On the surface, the deal isn’t that bad for Elan. Freeing up the change-in-control provision also makes it a more attractive takeout candidate, and Elan now has a sizable chunk of cash to stock its pipeline with.

The latter is likely what’s worrying investors. Management hasn’t exactly been the best steward of the company’s cash. Use of private jets, for instance, have been a sore subject with investors, especially as the drugmaker laid off workers.

This could be a win-win deal if Tysabri sales continue to grow and Elan makes good use of its new-found wealth. The former seems likely, but I think investors are right to be questioning the latter.

The article A Win-Win Multiple Sclerosis Deal? originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

The Top 10 Richest Actors in the World

The 10 Best Airline Stocks to Invest In Before They Fly Too High

Burger Kings: The 10 Most Expensive Burgers in the World

The 10 Most Ethnically Diverse Countries in the World

The 10 Most Exclusive Credit Cards in the World

The 10 Most Expensive Cruise Ships in the World

The 10 Fastest Supercomputers in the World

The 10 Best Countries for Doing Business 2015

6 Most Expensive Fruits In The World

10 Worst Airlines in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!